DBV Technologies (NASDAQ:DBVT) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report issued on Sunday. The firm set a “hold” rating on the stock.

Separately, JMP Securities reaffirmed a “market outperform” rating and set a $10.00 price objective on shares of DBV Technologies in a research report on Friday, January 10th.

DBV Technologies Price Performance

Shares of NASDAQ:DBVT opened at $6.20 on Friday. The firm has a market capitalization of $127.53 million, a PE ratio of -1.38 and a beta of 0.71. DBV Technologies has a 1 year low of $2.20 and a 1 year high of $8.32. The firm’s 50-day moving average is $4.45 and its two-hundred day moving average is $3.85.

Institutional Trading of DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC bought a new position in DBV Technologies S.A. (NASDAQ:DBVT) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies as of its most recent filing with the Securities and Exchange Commission. 71.74% of the stock is owned by hedge funds and other institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.